

References

- Abbott, KC, Bucci, JR, Cruess, D: Graft loss and acute coronary syndromes after renal transplantation in the United States. *J Am Soc Nephrol* 2002; 13: 2560-2564.
- Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Koff JM, Holtzmuller KC, Schnitzler MA: Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. *J Am Soc Nephrol*. 2004 Dec; 15 (12): 3166-3174.
- Abbott, KC, Yuan, CM, Taylor, AJ: Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression. *J Am Soc Nephrol* 2003; 14: 2358-2364.
- Ahsan N, Hricik D, Matas A, Rose S, Tomlanovich S, Wilkinson A, Ewell M, McIntosh M, Stablein D, Hodge E: Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil-a prospective randomized study. Steroid Withdrawal Study Group. *Transplantation* 1999 Dec 27; 68(12): 1865-74.
- Alak AM. Measurement of tacrolimus (FK 506) and its metabolites: a review of assay development and application in therapeutic drug monitoring development and application in therapeutic drug monitoring and pharmacokinetic studies. *Ther Drug* 1997; 19: 338-351.
- Almawi WY, Melemedjian OK, Rieder MJ: An alternate mechanism of glucocorticoid anti-proliferative effect: promotion of a Th2 cytokine-secreting profile. *Clin Transplant* 1999; 13: 365-374.

Almond MK, Kwan JT, Evans K, Cunningham J: Loss of regional bone mineral density in the first 12 months following renal transplantation. *Nephron* 1994; 66 (1): 52-57.

Ansell BM: Overview of the side effects of corticosteroid therapy. *Clin Exp Rheumatol* 1991; 9 (Suppl. 6): 19-24.

Aroldi A, Tarantino A, Montagnino G, Cesana B, Cocucci C, Ponticelli C: Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study. *Transplantation* 1997 Feb 15; 63 (3): 380-386.

Baden L, Katz J: Infectious disease issues in the well transplant patient. *Graft* 2001; 4: 276-283.

Bahra M, Neumann UI, Jacob D, Puhl G, Klupp J, Langrehr JM, Berg T, Neuhaus P: MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. *Am J Transplant* 2005 Feb; 15 (2): 406-411.

Berg, AL, Nilsson-Ehle, P: ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. *Kidney Int* 1996; 50: 538-543.

Bierer BE, Hollander G, Fruman D, Burakoff SJ: Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. *Curr Opin Immunol.* 1993 Oct; 5(5): 763-773.

Birkeland SA: Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. *Transplantation* 1998 Nov 15; 66(9): 1207-1210.

REFERENCES

- Birkeland SA: Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients. *Transplantation* 2001 Apr 27; 71(8): 1089-1090.
- Birkeland SA, Larsen KE, Rohr N: Pediatric renal transplantation without steroids. *Pediatr Nephrol*. 1998 Feb; 12(2): 87-92.
- Blaufox MD. Procedures of choice in renal nuclear medicine. *J Nucl Med*. 1991 Jun; 32(6): 1301-1309.
- Bloom, RD, Rao, V, Weng, F, et al. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. *J Am Soc Nephrol* 2002; 13: 1374-1378.
- Boots JM, Christiaans MH, Van Duijnhoven EM. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. *Transplantation* 2002; 74: 1703-1709.
- Borger M, Guest, Ganadoux MF: Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation. *J Pediatr* 1992; 120: 721-725.
- Borrows R, Loucaidou M, Tromp JV, Cairns T: Steroid Sparing with Tacrolimus and Mycophenolate Mofetil in Renal Transplantation-*Am J Transplant*: 2004; 4: 1845-1851.
- Bostom, AG, Shemin, D, Lapane, KL: Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study. *Atherosclerosis* 1996; 125:91-97.
- Boudreaux JP, McHugh L, Canafax DM, Ascher N, Sutherland DE, Payne W, Simmons RL, Najarian JS, Fryd DS: The impact of

cyclosporine and combination immunosuppression on the

incidence of posttransplant diabetes in renal allograft recipients.
Transplantation 1987 Sep; 44(3):376-381.

Braun W, Kallen J, Mikol V, Walkinshaw MD, Wuthrich K: Three-dimensional structure and actions of immunosuppressants and their immunophilins. Graft 1995 Jan; 9(1):63-72.

Budde K, Neumayer HH, Rostaing L, Cantarovich D, Mourad G, Rigotti P: Steroid free immunosuppression with daclizumab, tacrolimus, and MMF is efficacious and improves cholesterol, glucose, and bone mineral density-the CARMEN study. Transplantation 2004; 78: 168-172.

Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G: Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002 Sep; 62(3): 1060-1067.

Chakrabarti, P, Wong HY, Scantlebury, VP, et al. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 2000; 70:760-766

Chan L, Gaston R, Hariharan S: Evolution of Immunosuppression and continued importance of acute rejection in renal transplantation. Am J kidney Dis 2001; 38: p52- 59.

Chisholm MA: Issues of adherence to immunosuppressant therapy after solid-organ transplantation. Drugs 2002; 62: 567-571.

Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roth D, Kupin W, Nicolas M, Ruiz P, Rosen A, Miller J: A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and

- mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. *Transplantation* 2004 Jan 27; 77(2): 244-251.
- Ciancio G, Burke GW, Miller J: Current treatment practice in immunosuppression. *Expert Opin Pharmacother*. 2000 Dec; 1(7): 1307-1330.
- Citterio F.: Steroid side effects and their impact on transplantation outcome. *Transplantation* 2001; Dec 27; 72 (12 Suppl): 75-80.
- Citterio F, Rigotti P, Scata MC: Steroid withdrawal from tacrolimus-based therapy in renal transplant patients. *Transplant Proc* 2002; 34: 1707-1711.
- Cockcroft DW and Gault MH: Prediction of creatinine clearance from serum creatinine. *Nephron* 1976; 16: 31-39.
- Cole E, Landsberg D, Russell D: A pilot study of Steroid-free Immunosuppression in the prevention of acute rejection in renal allograft recipients. *Transplantation* 2001 Sep 15; 72: 845-850.
- Cosio FG, Pelletier RP, Pesavento TE, Henry ML, Ferguson RM, Mitchell L, Lemeshow S: Elevated blood pressure predicts the risk of acute rejection in renal allograft recipients. *Kidney Int* 2001 Mar; 59(3): 1158-1164.
- Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM: Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. *Kidney Int*. 2002 Oct 62(4): 1440-1446.
- Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM: Post-transplant diabetes mellitus: increasing incidence in renal allograft

recipients transplanted in recent years. *Kidney Int* 2001 Feb; 59(2): 732-737.

Cronin DC 2nd, Bruce DS, Newell KA, Josephson MA, Millis JM, Piper JB, Ruebe M, Kirby M, Thistlethwaite JR Jr, Woodle ES: Tacrolimus therapy for refractory renal allograft rejection: experience with steroid withdrawal. *Transplant Proc* 1997 Feb-Mar; 29(1-2): 307-312.

Danovitch GM: Immunosuppressive medications and protocols for kidney transplantation, in Danovitch GM (ed): *Hand book of kidney transplantation* (ed4). Philadelphia, PA, Lippincott Williams & Wilkins, 2005, pp 62-110.

Daoud AJ, Schroeder TJ, Shah M, Hariharan S, Peddi VR, Weiskittel P, First MR: A comparison of the safety and efficacy of mycophenolate mofetil, prednisone and cyclosporine and mycophenolate mofetil, and prednisone and tacrolimus. *Transplant Proc.* 1998 Dec; 30(8): 4079-4081.

d'Apice AJ, Becker GJ, Kincaid-Smith P, Mathew TH, Ng J, Hardie IR, Petrie JJ, Rigby RJ, Dawborn J, Heale WF: A prospective randomized trial of low-dose versus high-dose steroids in cadaveric renal transplantation. *Transplantation* 1984 Apr; 37(4): 373-377

Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernandez D, Kasiske BL, Kiberd B, Krentz A, Legendre C, Marchetti P, Markell M, van der Woude FJ, Wheeler DC: International Expert Panel.: New-onset diabetes after transplantation: 2003 International consensus guidelines. *Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003.* *Transplantation* 2003 May 27; 75(10 Suppl): 21-24.

REFERENCES

- DE Hricik, WL Kupin and MR First: Steroid-free immunosuppression after renal transplantation. *J Am Soc Nephrol* 1994Suppl 4, S10-S16.
- De Paulis A, Cirillo R, Ciccarelli A, Condorelli M, Marone G: FK 506, a potent novel inhibitor of the release of pro-inflammatory mediators from human Fce RI + cells. *J Immunol* 1991; 146: 2374-2379.
- Dimeny, EM: Cardiovascular disease after renal transplantation. 2002; 61(Suppl 80):S78-83.
- Drachenberg CB, Klassen DK, Weir MR, Wiland A, Fink JC, Bartlett ST, Cangro CB, Blahut S, Papadimitriou JC: Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. *Transplantation* 1999 Aug 15; 68(3): 396-402.
- Drueke TB, Abdulmassih Z, Lacour B, Bader C, Chevalier A, Kreis H: Atherosclerosis and lipid disorders after renal transplantation. *Kidney Int Suppl.* 1991 Apr; 31: S24-32.
- Ducloux D, Motte G, Vautrin P, Bresson-Vautrin C, Rebibou JM, Chalopin JM.: Polycystic kidney disease as a risk factor for post-transplant diabetes mellitus. *Nephrol Dial Transplant* 1999 May; 14(5): 1244-1249.
- Ducloux, D, Kazory, A, Chalopin, JM: Predicting coronary heart disease in renal transplant recipients: A prospective study. *Kidney Int* 2004; 66:441.
- Dumler F, Levin NW, Szego G, Vulpetti AT, Preuss LE.: Long-term alternate day steroid therapy in renal transplantation. A controlled study. *Transplantation* 1982 Aug; 34(2): 78-82.

REFERENCES

- Dumont FJ, Staruch MJ, Koprak SL, Siekierka JJ, Lin CS, Harrison R:
The immunosuppressive and toxic effects of FK 506 are
mechanistically related: pharmacology of a novel antagonist of FK
506 and rapamycin. *J Exp Med* 1992; 176: 751-760.
- Dussol, B, Bonnet, JL, Sampol, J: Prognostic value of inducible
myocardial ischemia in predicting cardiovascular events after renal
transplantation. *Kidney Int* 2004; 66:1633-1639.
- Ekberg H, Backman L, Tufveson G: Daclizumab prevents acute rejection
and improves patient survival post transplantation: 1 year pooled
analysis. *Transplant Int* 2000, 13: 151-159.
- Elias TJ, Bannister KM, Clarkson AR, Russ GR, Mathew TH, Barratt LJ,
Faull RJ: Excellent long-term graft survival in low risk, primary
renal allografts treated with prednisolone- avoidance
immunosuppression. *Clin Transplant* 2000 Apr 14(2): 157-161.
- Elster E, Chamberlin C, Salaita C, Kirk AD, Hale D, Mannon R: Steroids
have no calories: weight gain post transplantation is not prevented
by steroid avoidance. *Transplantation* 2004; 78: 170-175.
- European Multicenter Trial Group. European multicenter trial of
cyclosporine in renal transplantation: 10-year follow-up.
Transplant Proc 1993; 25: 527-529.
- Fellstrom B: Risk factors for and management of post-transplantation
cardiovascular disease. *Bio Drugs* 2001; 15: 261-265.
- Ferron GM, Jusko WJ: Clinical pharmacokinetics and
pharmacodynamics of glucocorticoids in transplant patients. *Graft*
1999; 2(5): 182-186.

REFERENCES

- Fine RN, Yadin O, Nelson PA, Pyke-Grimm K, Boechat MI, Lippe BH, Sherman BM, Ettenger RB, Kamil E: Recombinant human growth hormone treatment of children following renal transplantation. *Pediatr Nephrol*. 1991 Jan 5(1): 147-151.
- Friedman AN, Miskulin DC, Rosenberg IH, Levey AS: Demographics and trends in overweight and obesity in patients at time of kidney transplantation. *Am J Kidney Dis* 2003 Feb; 41(2): 480-487.
- Gaston RS: Maintenance immunosuppression in the renal transplant recipient: An overview. *Am J kidney Dis* 2001; 38: 25-35.
- Gaston RS, Basadorina G, Cosio FG, Davis CL, Kasiske BL, Larsen J, Leichtman AB, Delmonico FL: National Kidney Foundation Task Force on Diabetes and Transplantation.: Transplantation in the diabetic patient with advanced chronic kidney disease: a task force report. *Am J Kidney Dis* 2004 Sep 44(3):529-542.
- Gjertson DW: A multi-factor analysis of kidney outcomes at one and five years post-transplantation: 1996 UNOS update. In *Clinical Transplants 1996*, Terasaki PI (Ed), UCLA Tissue Typing laboratory, Los Angeles, 1997, P 343-346.
- Gonwa T, Johnson C, Ahsan N: Randomized trial of tacrolimus _ mycophenolate mofetil or azathioprine versus cyclosporine_ mycophenolate mofetil after cadaveric kidney transplantation: results at three years. *Transplantation* 2003; 75: 2048-2052.
- Gourishankar S, Jhangri GS, Tonelli M, Wales LH, Cockfield SM: Development of diabetes mellitus following kidney transplantation: a Canadian experience. *Am J Transplant*. 2004 Nov; 4(11):1876-1882.

REFERENCES

- Grewal HP, Thistlethwaite JR: Early corticosteroid withdrawal 1 week following renal transplantation using tacrolimus/ mycophenolate based immunosuppression. *Transplant Proc* 1998; 30: 1378 – 1379.
- Griffiths MH, Growe AV, Papadaki L: Cyclosporine nephrotoxicity in heart and lung transplant patients. *Q J Med* 1996; 89: 751-755.
- Grinyo JM, Gil-Vernet S, Seron D, Cruzado JM, Moreso F, Fulladosa X, Castela AM, Torras J, Hoofman L, Alsina J: Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients. *Transplantation* 1997 Jun 15; 63(11): 1688-1690.
- Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ: Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. *Transplantation* 1994 Oct 27; 58 (8): 912-915.
- Grotz WH, Mundinger FA, Rasenack J, Speidel L, Olschewski M, Exner VM, Schollmeyer PJ: Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. *Nephrol Dial Transplant* 1995 Nov; 10(11): 2096-2100.
- Guijarro C, Keane, WF: Lipid abnormalities and changes in plasma proteins in glomerular diseases and chronic renal failure. *Curr Opin Nephrol Hypertens* 1993; 2: 372-37
- Guijarro C, Massy ZA, Kasiske BL: Clinical correlation between renal allograft failure and hyperlipidemia. *Kidney Int* 1995; Suppl 52: 56-61.
- Gunnarsson R, Arner P, Lundgren G, Magnusson G, Ostman J, Groth CG: Diabetes mellitus-a more-common-than-believed

REFERENCES

- complication of renal transplantation. *Transplant Proc* 1979 Jun; 11(2): 1280-1281.
- Gunnarson R, Lofmark KR, Lordlander R: Acute myocardial infarction in renal transplant recipients: incidence and prognosis. *Eur Heart J* 1984; 5: 218. 25-29.
- Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J: Glucocorticoids and the risk for initiation of hypoglycemic therapy. *Arch Intern Med* 1994 Jan 10; 154(1): 97-101.
- Hans WS, Stephen CR: Mycophenolate mofetil, current opinion in organ transplantation. *Transplantation* 1997; 2: 54-61.
- Hariharan S: Long-Term kidney transplant survival. *Am J kidney Dis* 2001. 38: 44-50.
- Hariharan S, Adams MB, Brennan DC: Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). *Transplantation* 1999, 68:635-638.
- Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D: Improved graft survival after renal transplantation in the United States, 1988 to 1996. *N Eng J Med* 2000; 342: 605-612.
- Hariharan S, McBride MA, Bennett LE, Cohen EP: Risk factors for renal allograft survival from older cadaveric donors. *Transplantation* 1997; 64: 1748-1754.
- Hata Y, Ozawa M, Takemoto S: HLA matching. In: *Clinical Transplants* 1996, Terasaki PI (Ed), UCLA Tissue Typing laboratort, Los Angeles, 1997, P. 381.

REFERENCES

- Häyry P, Yilmaz S, Taskinen E, Isoniemi H: Intermediate efficacy endpoints for chronic kidney allograft rejection: implications of protocol core biopsy for early registration of new agents. In Lieberman R and Mukherjee A (Ed). Principles of Drug Development in Transplantation and Autoimmunity. RD Lanes Company, 1996, P. 557-564.
- Heisel O, Heisel R, Balshaw R, Keown P: New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004 Apr; 4(4): 583-595
- Hericik DE: Steroid Withdrawal in Renal Transplant Recipients: Pro point of view. Transplant Proc, 1998; 30: 1380- 1382.
- Hericik DE, Almawi WY, Strom T.B: Trends in the use of glucocorticoids in renal transplantation. Transplantation 1994; 57: 979-984.
- Hill, MN, Grossman, RA, Feldman, HI: Changes in causes of death after renal transplantation, 1966 to 1987. Am J Kidney Dis 1991; 17: 512-517.
- Hirano T, OKa K, Takeuchi H: Immunosuppressant pharmacodynamic on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis and psoriasis: possible implication for individual therapeutic efficacy. Clin Pharmacol Ther, 1997; 62: 652-664.
- Hirsch IB, Paauw DS: Diabetes management in special situations. Endocrinol Metab Clin North Am 1997 Sep; 26(3): 631-645.

REFERENCES

- Hjelmesaeth J, Hartmann A: Insulin resistance in patients with adult polycystic kidney disease. *Nephrol Dial Transplant*. 1999 Oct; 14(10): 2521-2523
- Hjelmesaeth J, Hartmann A, Kofstad J, Egeland T, Stenstrom J, Fauchald P: Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. *Nephrol Dial Transplant* 2001 Apr; 16(4): 829-835.
- Hjelmesaeth J, Hartmann A, Kofstad J, Stenstrom J, Leivestad T, Egeland T, Fauchald P: Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. *Transplantation* 1997 Oct 15; 64(7): 979-983.
- Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, Nourse J, Crabtree GR: The mechanism of action of cyclosporin A and FK506. *Clin Immunol Immunopathol* 1996 Sep; 80(3 Pt 2): 40-45.
- Hollander AA, Hene RJ, Hermans J, van Es LA, van der Woude FJ: Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. *J Am Soc Nephrol* 1997 Feb; 8(2): 294-301.
- Hricik, DE: The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. *Transplantation* 1992; 54: 868.
- Hricik DE, Knauss TC, Bodziak KA: Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. *Transplantation* 2003; 76: 938-942.

REFERENCES

- Hricik DE, Kupin WL, First MR: Steroid-free immunosuppression after renal transplantation. J Am Soc Nephrol 1994; 4(Suppl 1): S10-S16.
- Hricik, DE, Lautman, J, Bartucci, MR: Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine treated renal transplant recipients. Transplantation 1992; 53: 1232-1237
- Hricik DE, O'Toole MA, Schulak JA: Steroid-free immunosuppression in cyclosporine treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993; 4: 1300-1305.
- Hricik DE, Whalen CC, Lautman J: Withdrawal of steroids after renal transplantation--clinical predictors of outcome. Transplantation 1992; 53: 41-45.
- Hutchinson IV: The mode of action of prograf (tacrolimus) and its significance for long term graft survival. New Horiz Kid Transplant 1997; 1 (1): 22-26.
- Incenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A: Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3: 306-311.
- Isoniemi H: Renal allograft immunosuppression. III. Triple therapy versus three different combinations of double drug treatment: two year results in kidney transplant patients. Transplat Int 1991 Apr; 4(1):31-7.

REFERENCES

- Isoniemi HM, Krogerusl, Von Willebrand E, Taskinen E, Ahonen J and Hayry P: Histopathological findings in well-functioning, long term renal allografts. *Kidney Int* 1992, 41: 155-160.
- Jabs K, Sullivan EK, Avner ED, Harmon WE: Alternate day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A Report of the North American Pediatric Renal Transplant Cooperative Study. *Transplantation* 1996; 61: 31-37.
- Jensik SC: Tacrolimus (FK 506) in kidney transplantation: Three-year survival results of the US Multicenter, Randomized, Comparative trial. FK 506 Kidney Transplant Study Group. *Transplant Proc* 1998; 30: 1216-1218.
- Jindal M, Sidner R A: Safety and tolerability of simulect, tacrolimus, cellcept and prednosone in recipients of kidney transplants. *Transplantation* 1999, 67: S154, 589.
- Jindal RM, Baines LS: Noncompliance after solid organ transplantation. *Transplantation* 2001; 72: 1583-1589.
- Jindal, RM, Zawada, ET: Obesity and kidney transplantation. *Am J Kidney Dis* 2004; 43: 943-948.
- Johnson DB, Lerner CA, Prince MR: Gadolinium enhanced magnetic resonance angiography of renal transplants. *Magn Reson Imaging* 1997, 15, 13-19.
- Johnson R, Mayer G, Kreis H, Brattstrom C, Claesson K, Eris J: Sirolimus allows early CsA elimination in renal transplantation: concentration-controlled therapy with a new tablet formulation.

REFERENCES

Presented at the XVIII the International congress of transplantation society, Rome, Italy, August 27- September 1, 2000 Abstract.

Johnson RWG: The clinical impact of nephrotoxicity in renal transplantation. *Transplantation* 2000; 69: 14-17.

Jordan ML, Shapiro R, Vivas CA, Scantlebury VP, Rhandhawa P, Carrieri G, McCauley J, Demetris AJ, Tzakis A, Fung JJ: FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. *Transplantation* 1994 Mar 27; 57(6): 860-865.

Kahan BD: Emerging strategies for the clinical application of rapamycin. *Clin Biochem* 1998; 31: 341-4.

Kahan BD, Rajagopalan PR, Hall M: Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. *Transplantation* 1999; 67: 276-280.

Kamel K, Ethier JH, Quaggin S: Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine. *J Am soc Nephrol* 1992; 2: 1279-1283.

Kasiske BL: Risk factors for accelerated atherosclerosis in renal transplant recipients. *Am J Med* 1988; 84: 985-989.

Kasiske BL: A meta-analysis of immunosuppression withdrawal trials in renal transplantation. *J Am Soc Nephrol* 2000; 11: 1910-1915.

Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, Rush DN, Vazquez MA, Weir MR: American Society of

Transplantation The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2001; 1 Suppl 2: 3-95.

Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003 Feb; 3(2): 178-185.

Kershner RP, Fitzimmons WE: Relationship of FK 506 whole blood concentration and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62: 920-926.

Khwaja K, Asolati M, Harmon J, Matas A J: Outcome at 3 Years with a Prednisone- Free Maintenance Regimen: A single- center Experience with 349 kidney Transplant Recipients. Am J Transplantation 2004; 4: 980- 987

Knechtle SJ, Pirsch JD, Fechner H Jr: Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722-730.

Kobashigawa JA, Katznelson S, Laks H: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-625.

Kovarik J M, Rawlings E: Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation. Transplant Proc 1996 Apr 28 (2): 913-917.

Kovarik J, Wolf P: Disposition of Basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 1997 Dec 27; 64: 1701-1705.

- Kreis HA, Ponticelli C: Causes of late renal allograft loss: chronic allograft dysfunction, death, and other factors. *Transplantation* 2001; 71: 5-11.
- Kubo T, Fujioka M, Yamazoe S, Yoshimura N, Oka T, Ushijima Y: Relationship between steroid dosage and osteonecrosis of the femoral head after renal transplantation as measured by magnetic resonance imaging. *Transplant Proc* 1998; 30: 3039-3040.
- Kuypers DR, Evenepoel P, Maes B: The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. *Clin Transplant* 2003; 17: 234-237.
- Lehtonen SR, Taskinen E, Isoniemi H: Histological alteration in implant and one year protocol biopsy specimens of renal allografts. *Transplantation* 2001; 72: 1138-1144.
- Lemieux I, Houde I, Pascot A: Effects of Prednisone Withdrawal on the new metabolic triad in cyclosporine-treated Kidney transplant patients. *Kidney Int* 2002; 62: 1839-1843.
- Lerut JP: Avoiding Steroid in Solid Organ Transplantation. *Transplant Int* 2003, 16: 213- 224.
- Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. *Cell* 1991 Aug 23; 66(4): 807-815.
- Loghman-Adham M: Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. *Am J Manag Care* 2003; 9: 155-159.

REFERENCES

- Maes BD, Kuypers D, Messiaen T, Evenepoel P, Mathieu C, Coosemans W, Pirenne J, Vanrenterghem YF: Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. *Transplantation* 2001 Nov 27;72(10):1655-1661.
- Makita, Z, Yanagisawa, K, Kuwajima, S: The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis. *Nephrol Dial Transplant* 1996; 11:31-36.
- Mange KC, Joffe MM, Feldman HI: Effect of the use or non use of long term dialysis on the subsequent survival of renal transplants from living donors. *N Engl J Med* 2001; 344: 726-732.
- Margreiter R: Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. *Lancet* 2002; 359: 741-745.
- Markell M.: New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management. *Am J Kidney Dis* 2004 Jun; 43(6): 953-965.
- Matas AJ, Gillingham KJ, Humor A: Immunologic and non-immunologic factors: different risks for cadaver and living donor transplantation. *Transplantation* 2000; 69:54-59.
- Matas AJ, Gillingham KJ, Payne WD, Najarian JS: The impact of an acute rejection episode on long-term renal allograft survival. *Transplantation* 1994; 57: 857-859.
- Matas AJ, Humar A, Gillingham KJ, et al. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. *Kidney Int* 2002; 62: 704-708.

REFERENCES

- Matas AJ, Kandaswamy R, Humar A: Long-term immunosuppression without maintenance prednisone, after kidney transplantation. *Ann Surg* 2004; 240: 510-517.
- Matas AJ, Ramcharan T, Paraskevas S, Gillingham KJ, Dunn DL, Gruessner RW, Humar A, Kandaswamy R, Najarian JS, Payne WD, Sutherland DE: Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. *Am J Transplant*. 2001 Sep;1(3):278-283.
- Mathew A, Talbot D, Minford EJ: Reversal of steroid resistant rejection in renal allograft recipients using FK 506. *Transplantation* 1995; 60 (10): 1187-1194.
- Mathew T, Häyry P, Yilmaz S, Navarro M and Romos E: High 1-year chronic allograft damage index (CADI) significantly predicts 3-year Graft Loss and Death in Renal Transplant recipients. 4th International Conference on new trends in clinical and experimental immunosuppression in Geneva, Switzerland, February 17-20, 2000 Abstract.
- Mathew TH: A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. *Transplantation* 1998 Jun 15; 65(11): 1450-1454.
- Mauiyyedi S, Pelle PD, Saidman S, Collins AB, Pascual M, Tolkoff-Rubin NE, Williams WW, Cosimi AA, Schneeberger EE, Colvin RB: Chronic humoral rejection. Identification of antibody mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. *J Am Soc Nephrol* 2001; 12:574-582.

- Mayer AD: Chronic rejection and graft half-life: five-year follow-up of the European tacrolimus multicenter renal study. *Transplant Proc* 2002; 34: 1491-1495.
- Mayer AD, Dmitrevski J, Squifflet J-P: Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. *Transplantation* 1997; 64: 436-441.
- McCune TR, Thacker LR, Peters TG: Effects of tacrolimus on hyperlipidemia after successful renal transplantation, a Southeastern Organ Procurement Foundation multicenter clinical study. *Transplantation* 1998; 65: 87-93.
- Meier-Kriesche HU, Baliga R, Kaplan B: Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. *Transplantation* 2003; 75:1291-1295.
- Meiser BM, Pfeiffer M, Schmidt D, Reichenspurner H, Ueberfuhr P, Paulus D, von Scheidt W, Kreuzer E, Seidel D, Reichart B: Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. *J Heart Lung Transplant* 1999 Feb; 18(2): 143-149.
- Mendez R.: FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group. *Transplant Proc* 1998 Jun; 30(4): 1287-1289.
- Michelson TF, Piovesan F, Pozza R: Noncompliance as a cause of renal graft loss. *Transplant Proc* 2002; 34: 2768-2772.

REFERENCES

- Midtvedt K, Hjelmessaeth J, Hartmann A, Lund K, Paulsen D, Egeland T, Jenssen T: Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. *J Am Soc Nephrol.* 2004 Dec;15(12): 3233-3239.
- Mihatsch MJ, Ryffel B, Gudat F: The differential diagnosis between rejection and cyclosporine toxicity. *Kidney Int* 1995; 48 (suppl 52): 63-69.
- Miller J: Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. FK506/MMF Dose-Ranging Kidney Transplant Study Group. *Transplant Proc.* 1999 Feb-Mar 31(1-2): 276-283.
- Miller J, Ciancio G, Burke GW, Suzart K, Roth D, Kupin W, Rosen A, Olson L, Esquenazi V: Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. *Transplantation* 2002 Apr 15; 73(7):1100-1106.
- Miller J, Mendez R, Pirsch JD, Jensik SC: Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. *Transplantation* 2000 Mar 15; 69(5): 875-880.
- Miller J, Pirsch JD, Deierhoi M, Vincenti F, Filo RS: FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group. *Transplant Proc.* 1997 Feb-Mar; 29(1-2): 304-309.
- Montagnino G, Kramer BK, Arias M: Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in kidney

transplantation: Twelve-month follow-up. Transplant Proc 2002; 34: 1635-1640.

Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC: Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002 Mar; 25(3): 583-592.

Morris PE: The immunology of rejection in kidney transplantation: principles and practice (3d edition). Edited by Morris PE, New York, London, Orlando, Grune and Stratton 1988, PP 15-32.

Morris PJ: Azathioprine and Steroids. In: Peter J Morris (eds): Kidney Transplantation ; Principles and Practice , 5th ed .W B Saunders company ,USA, 2003, PP 217-26.

Moruzumi K, Gudat F, Thie LG: IS Cyclosporine A associated glomerulopathy a new glomerular lesion in renal allografts using CsA? At: 14th International congress of the Transplantation Society, August 6-21, 1992 Abstract.

Nashan B: Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997 Nov; 350: 190-198 .

Nashan B, Moore R: Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997 Oct 25; 350 : 1193-1198.

Neylan JF: Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation. 1998 Feb 27; 65(4):515-523.

REFERENCES

- Ojo AO, Hanson JA, Wolfe RA: Long-term survival in renal transplant recipients with graft function. *Kidney Int* 2000; 57: 307-311.
- Ojo AO, leichtman AB, Punch JD: Impact of pre-existing donor hypertension and diabetes Mellitus on cadaveric renal transplant outcomes. *Am J kidney Dis* 2000; 36:153-159.
- Ojo AO, Meier-kriesche HU, Hanson JA, leichtman AB, Cibrik D, Magee JC, Wolfe RA, Agdoaly, Kaplan B: Mycophenolate Mofetil reduces late renal allograft loss independent of acute rejection. *Transplantation* 2000; 69: 2405-2409.
- Oplez G: Effect of the maintenance immunopressive drug regimen on kidney transplant outcome. *Transplantation* 1998; 58: 443.
- Opelz G, Dohler B, Laux G: Collaborative Transplant Study: Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. *Am J Transplant* 2005 Apr; 5(4 Pt 1): 720-728.
- Opelz G, Laux G, Dohler B: Results of a prospective steroid withdrawal study in 1010 cadaver kidney and 385 heart transplant recipients. *Transplantation* 2004; 78: 168-172.
- Oplez G, Wujeiak T, Ritz E: Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. *Kidney Int* 1998; 53: 217-222.
- Parker SH, Happer KB and Yakes WF: Image directed percutaneous biopsies with a biopsy gun. *Radiol* 1989; 171: 663-669.
- Parrott NR, Hammad AQ, Watson CJ, Lodge JP, Andrews CD. Multicenter, randomized study of the effectiveness of basiliximab

REFERENCES

in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients. *Transplantation* 2005 Feb 15;79(3):344-348.

Pascual J, Quereda C, Zamora J, Hernandez D: Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. *Transplantation* 2004 Nov 27; 78(10): 1548-1556.

Pascual M, Theruvath T, Kawai T: Strategies to improve longterm outcomes after renal transplantation. *N Engl J Med* 2002; 346: 580-584.

Paul LC: Overview of side effects of immunosuppressive therapy. *Transplant Proc* 2001; 33: 2089-2095.

Pirsch JD: Long term management of immunosuppression in the renal patients. *Curr Opin in Organ Transplant* 1997; 2: 76-81.

Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS :A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK 506 kidney transplant study group. *Transplantation* 1997; 63: 977-983.

Ponticelli C: Progression of renal damage in chronic rejection. *Kidney Int* 2000; 57 (suppl 75): 562-570.

Ponticelli C, Sandrini S, Casciani C, Schena FP.: A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine. *Transplantation* 2004; 78: 170-175.

REFERENCES

- Porayko MK, Textro SC, Krom RA: Nephrotoxic effects of primary immunosuppression with FK 506 and cyclosporine regimens after transplantation. *Mayoclin Proc* 1994; 69: 105-111.
- Racusen LC, Solez K, Colvin RB: The Banff 97 working classification of renal allograft pathology. *Kidney Int* 1999; 55 (2): 713-723.
- Ratcliffe PJ, Dudley CR, Higgins RM, Firth JD, Smith B, Morris PJ: Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. *Lancet* 1996 Sep 7;348:643-648.
- Rigatt C, Parfrey, P, Foley, R: Congestive heart failure in renal transplant recipients: Risk factors, outcomes, and relationship with ischemic heart disease. *J Am Soc Nephrol* 2002; 13:1084-1089.
- Rigotti P: Patients with high cholesterol levels benefit most from early withdrawal of corticosteroids. *Transplant Proc* 2002; 34: 1797-1802.
- Rizzoni G, Broyer M, Guest G, Fine R, Holliday MA: Growth retardation in children with chronic renal disease: scope of the problem. *Am J Kidney Dis* 1986 Apr; 7(4): 256-261.
- Roberti I, Reisman L, Lieberman KV, Burrows L: Risk of steroid withdrawal in Pediatric renal allograft recipients (a 5-year follow up). *Clin Transplant* 1994; 8: 405-410.
- Rogers CC, Alloway RR, Hanaway M, Buell JF, Roy- Chaudhury, Succop P, Woodle ES: Body weight, Alteration under Early Corticosteroid Withdrawal and Chronic Corticosteroid Therapy with Modern Immunosuppression. *Transplant Proc* 2005; 37: 800-801.

REFERENCES

- Rogers CC, Alloway RR, Trofe J, Woodle ES: Global Cardiovascular Risk Under Early Corticosteroid cessation Decreases Progressively in the First Year following Renal Transplantation. *Transplant Proc* 2005; 37, 812-813.
- Rubin JM, Platt JF, Alder RS: Application of Doppler in transplant and native kidney disease. *Ultrasound* 1999; Q 8: 95-120.
- Rush D, Nickerson P, Gough J, McKenna R, Grimm P, Cheang M, Trjokov K, Sölez k, Jeffery J: Beneficial effects of treatment of early subclinical rejection: A randomized study. *Am J Soc Nephrol* 1998; 9: 2129-2134.
- Samsel R, Chmura A, Włodarczyk Z, Wyzgal J, Cieciora T, Lagiewska B, Pliszczynski J, Korczak G, Lazowski T, Paczek L, Walaszewski J, Lao M, Rowinski W: Perioperative single high dose ATG-Fresenius S administration as induction immunosuppressive therapy in cadaveric renal transplantation--preliminary results. *Ann Transplant* 1999; 4(2): 37-39.
- Sandrini S, Maiorca R, Scolari F, Cancarini G, Setti G, Gaggia P, Cristinelli L, Zubani R, Bonardelli S, Maffei R, Portolani N, Nodari F, Giulini SM: A prospective randomized trial on azathioprine addition to cyclosporine versus cyclosporine monotherapy at steroid withdrawal, 6 months after renal transplantation. *Transplantation* 2000 May 15; 69(9):1861-1867.
- Sarnak MJ: Cardiovascular complications in chronic kidney disease. *Am J Kidney Dis* 2003 Jun; 41(5 Suppl): 11-17.
- Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J: Kidney disease as a risk factor for development of cardiovascular disease. *Circulation* 2003; 108: 2154-2159.

REFERENCES

- Sarwal MM, Yorgin PD, Alexander S, et al, Promising Early Outcomes with a Novel, Complete Steroid avoidance immunosuppression protocol in pediatric renal transplantation. *Transplantation* 2001; 72: 13-21.
- Sarwal MM, Yorgin PD, Alexander S, Millan MT, Belson A, Belanger N, Granucci L, Major C, Costaglio C, Sanchez J, Orlandi P, Salvatierra O Jr: Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. *Transplantation* 2001 Jul 15; 72(1): 13-21.
- Schmandt R, Hill M, Amendola A: IL2 induced expression of TTK, a serine, threonine, tyrosine kinase correlates with cell cycle progression. *J Immunol* 1994; 152: 96-105.
- Sehgal SN: Rapamune (Rapa, rapamycin, Sirolimus): Mechanism of action, immunosuppressive effect, results from blockade of signal transduction and inhibition of cell cycle progression. *Clin Biochem* 1998; 31: 335-340.
- Sethu G, Alloway R, Hanaway M: Early corticosteroid withdrawal under modern immunosuppression in renal transplantation: multivariate analysis of risk factors for acute rejection. *Transplantation* 2004; 78: 170-171.
- Shapiro R, Jordan ML, Basu A: Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. *Ann Surg* 2003; 238: 520-525.
- Shapiro R, Jordan ML, Scantlebury YP, Vivas C, Gritsch HA, McCauley J, Mc Quitty D, Randhawa P, Irish W, Mc Michael J, Hakala TR, Simons RL, Fung JJ, Starzl TE: Outcome After Steroid

REFERENCES

- Withdrawal in Renal Transplant Patients Receiving Tacrolimus-Based Immunosuppression. *Transplant Proc* 1998; 30: 1375- 1377.
- Shapiro R, Young JB, Milford El: Immunosuppression evolution in practice and trends, 1993- 2003. *Am J Transplant* 2005; 5: 874- 886.
- Shun-Shin GA, Ratcliffe P, Bron AJ, Brown NP, Sparrow JM: The lens after renal transplantation. *Br J Ophthalmol* 1990 May; 74(5):267-271.
- Sinclair NR: Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. *CMAG* 1992 Sep 1; 147(5): 645-57.
- Sivaraman P, Nussbaumer G, Landsberg D: Lack of long-term benefits of steroid withdrawal in renal transplant recipients. *Am J Kidney Dis* 2001 Jun; 37(6):1162-1169.
- Slakey DP, Johnson CP, Cziperle DJ, Roza AM, Wittmann DH, Gray DW, Roake JA, Britton J, Morris PJ, Adams MB: Management of severe pancreatitis in renal transplant recipients *Ann Surg* 1997 Feb;225(2):217-222.
- Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, Hoitsma AJ, Hene RJ, Weimar W, Hilbrands LB, van Gelder T: Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. *J Am Soc Nephrol* 2002 May;13(5):1365-1373.
- Solez K, Vincenti F, Filo RS: Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK 506

REFERENCES

- kidney transplant study Group. Transplantation 1998; 66: 1736-1741.
- Sollinger HW: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995 Aug 15; 60(3): 225-232.
- Sota E, Alferez MJ, Cabello M: Low-dose and rapid steroid withdrawal in renal transplant patients treated with tacrolimus and mycophenolate mofetil. Transplant Proc 2002; 34: 1689-1893.
- Squifflet JP, Vanrenterghem Y, van Hooff JP: Safe withdrawal Of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. Transplant Proc 2002; 34: 1584-1589.
- St. Sinclair NR: Canadian Multicentre Transplant Study Group. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. Can Med Assoc J 1992; 147: 645-657.
- Starzl TE, Marchioro TI, Waddell Wr: The Reversal Of Rejection In Human Renal Homografts With Subsequent Development Of Homograft Tolerance. Surg Gynecol Obstet Oct; 117: 385-95, 1963.
- Sumrani NB, Delaney V, Ding ZK, Davis R, Daskalakis P, Friedman EA, Butt KM, Hong JH: Diabetes mellitus after renal transplantation in the cyclosporine era--an analysis of risk factors. Transplantation 1991 Feb; 51(2): 343-347.

- Suthanthiran M, Morris RE, Storm TB: Immunosuppressant: cellular and molecular mechanisms of action. *Am J kidney Dis* 1996; 28 (2): 159-172.
- Szezech LA, Berlin JA, Aradhye S: Effects of antilymphocyte induction on renal allograft survival: a meta analysis. *J Am Soc Nephrol* 1997; 8: 1771-1777.
- Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM: Twelve years experience with national sharing of HLA-matched cadaveric kidneys for transplantation. *N Engl J Med* 2000; 343: 1078-1084.
- Tejani A, Sullivan EK: The impact of acute rejection on chronic rejection: A report of the north American pediatric Renal Transplant Cooperative Study. *Pediatr Transplant* 2000; 4: 107-111.
- Ter Meulen CG, Riemsdijk IV, Hené RJ: Steroid- Withdrawal at 3 Days After Renal Transplantation with Ant:- IL- 2 Receptor α Therapy: A Prospective, Randomized, Multicenter Study. *Am J Transplant* 2004; 4: 803- 810.
- Teraoka S, Sato S, Sekijima H: Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF) and triple regimen consisting of CNI, MMF, and steroid. *Transplantation* 2004; 78: 169-174.
- Terasaki PI, Cecka JM, Gjertson DW et al.: Risk-rate and long term kidney transplant survival. In: *Clinical Transplants 1996*, Tersaki PI (Ed), UCLA Tissue Typing laboratory, Los Angeles 1997, p. 443.

- III The Mycophenolate Mofetil Acute Renal Rejection Study Group.
Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. *Transplantation* 2001; 71: 1091-1097.
- The Mycophenolate Mofetil Renal Refractory Rejection Study Group:
Mycophenolate Mofetil for the treatment of refractory acute cellular renal transplant rejection. *Transplantation* 1996; 61: 722-729.
- The US Multi-center FK 506 Liver Study Group A comparison of tacrolimus FK 506 and cyclosporine for immunosuppression in liver transplantation. *N Engl J Med* 1994 Oct 27; 331: 1110-1115.
- Tomlanovich SJ, Häyry P, Yilmaz S, Navarro M, Romos E: Correlation of serial biopsy data with term function and graft and patient survival in the US Renal Transplant Mycophenolate Mofetil Trial. American Society of Nephrology 32nd Annual Scientific Meeting in Miami, Florida, USA. November 5-8, 1999, Abstract.
- Van Duijnhoven EM, Boots JM, Christiaans MH, Stolk LM, Undre NA, van Hooff JP: Increase in tacrolimus trough levels after steroid withdrawal. *Transplant Int* 2003 Oct;16(10):721-725.
- Vanrenterghem Y: The use of Mycophenolate Mofetil (cellcept) in renal transplantation. *Nephron* 1997; 76: 392-399.
- Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H. :Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. *Transplantation* 2000 Nov 15; 70(9):1352-1359.

REFERENCES

- Vazquez MA: chronic rejection of renal transplants: New clinical insights. *Am J Med Sci* 2000; 320: 43-58.
- Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE: Incidence and long-term cost of steroid-related side effects after renal transplantation. *Am J Kidney Dis* 1999 May; 33(5):829-839.
- Vesco L, Busson M, Bedrossian J, Bitker MO, Hiesse C, Lang P: Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors. *Transplantation* 1996 May 27; 61(10): 1475-1478.
- Vincenti F: Immunosuppression minimization: current and future trends in transplant immunosuppression.: *J Am Soc Nephrol* 2003; 14: 1940-1948.
- Vincenti F: Role of monoclonal antibodies in renal transplantation *Transplantation* 2000 27; 69 (11): 576-582.
- Vincenti F, Jensik SC, Filo RS: A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. *Transplantation* 2002; 73: 775-779.
- Vincenti F, Iautz M, Bimbaum J, et al.: A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. *Transplantation* 1997, 63: 33-38.
- Vincenti F, Monaco A: A multicentre, randomised trial of rapid steroid withdrawal versus standard steroid treatment in patients treated with simulect, neoral, and cellcept for the prevention of acute rejection in renal transplantation. *Transplantation* 1999; 67 (7): 152-158.

REFERENCES

- Vincenti F, Monaco A, Grinyo J, et al.: Multicentre, randomized prospective trial of rapid steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. *Am J Transplant* 2003;3:306-311
- Vitko S, Klinger M, Salmela K, Wlodarczyk Z, Tyden G, et al.: Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. *Transplantation* 2005 Dec 27;80(12):1734-1741.
- Wagner K, Herget S, Heeman U: Experimental and clinical experience with the use of tacrolimus (FK 506) in kidney transplantation. *Clin Nephrol* 1996; 45: 332-335.
- Waldman WJ, Knight DA: Cytokine-mediated induction of endothelial adhesion molecule and histocompatibility leukocyte antigen expression by cytomegalovirus activated T cells. *Am J Pathol* 1996; 148: 105-110.
- Weir MR, Anderson L, Fink JC: A novel approach to the treatment of chronic allograft nephropathy. *Transplantation* 1998; 64: 1706-1711.
- Weir MR, Fink JC: Risk for post-transplant diabetes mellitus with current immunosuppressive medications. *Am J kidney Dis* 1999; 34: 390-394.
- Wiesel M, Carl S: A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year

REFERENCES

- results. The European Mycophenolate Mofetil Cooperative Study Group. *J Urol* 1998 Jan; 159(1): 28-33.
- Winkler M and Christians U: A risk benefit assessment of tacrolimus in transplantation. *Drug Safety* 1995; 12: 348-357.
- Wissing KM, Abramowicz D, Broeders N, Vereerstraeten P: Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. *Transplantation* 2000; 70: 464-472.
- Włodarczyk Z, Wałaszewski J, Perner F: Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients. *Ann Transplant* 2002; 7: 28-35.
- Woodle ES: A Prospective, Randomized, Multicenter, Double- Blind Study of Early Corticosteroid Cessation versus Long- Term Maintenance of Corticosteroid Therapy with Tacrolimus and Mycophenolate Mofetil in Primary Renal Transplant Recipients: One Year Report. *Transplant Proc* 2005; 37: 804- 808.
- Woodle ES, Thistlethwait JR, Gordan JH, Laskow D, Deierhoi MH, Burdick J, Pirsch JD, Sollinger H, et al: A multicenter trial of FK 506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the tacrolimus kidney transplantation Rescue study group. *Transplantation* 1996; 62: 594-599.
- Woodle ES, Vincenti F, Lorber M: A multicenter, open label pilot study of early (5 day) corticosteroid cessation in de novo renal transplant recipients under Simulect, Tacrolimus, and Sirolimus therapy: one year results. *Transplantation* 2004; 78: 169-175.

REFERENCES

- Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez-Rocafor L, Haider S, Woodworth TG, Brennan DC: Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. *Am J Transplant* 2003 May;3(5):590-598.
- Yatscoff RW, Aspeslet JL, Gallant HL: Pharmacodynamic monitoring of immunosuppressive drugs. *Clin Chem* 1998; 44: 428-432.
- Yeo, FE, Villines, TC, Bucci, JR: Cardiovascular risk in stage 4 and 5 nephropathy. *Adv Chronic Kidney Dis* 2004; 11:116-121.
- Zarifian A, Meleg-Smith S, O'donovan R, Tesi RJ, Batuman V. Cyclosporine-associated thrombotic microangiopathy in renal allografts. *kidney Int* 1999 Jun; 55: 2456-2466.
- Zekry A, Gleeson M, Guney S, McCaughan GW: A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. *Liver Transpl.* 2004Jan; 10(1): 52-57.
- Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J: Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. *Transplant Immunol* 1997 Sep; 5(3): 225-232.